These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 20368203)
1. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not? Reaven GM Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203 [No Abstract] [Full Text] [Related]
2. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264 [TBL] [Abstract][Full Text] [Related]
3. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. Ribbing J; Hamrén B; Svensson MK; Karlsson MO J Clin Pharmacol; 2010 Aug; 50(8):861-72. PubMed ID: 20484615 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic β cells: Gatekeepers of type 2 diabetes. Park YJ; Woo M J Cell Biol; 2019 Apr; 218(4):1094-1095. PubMed ID: 30696700 [TBL] [Abstract][Full Text] [Related]
5. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548 [No Abstract] [Full Text] [Related]
6. Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. Hanley AJ; Retnakaran R; Qi Y; Gerstein HC; Perkins B; Raboud J; Harris SB; Zinman B J Clin Endocrinol Metab; 2009 Oct; 94(10):3824-32. PubMed ID: 19622625 [TBL] [Abstract][Full Text] [Related]
7. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes. Curry A Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753 [No Abstract] [Full Text] [Related]
8. Serum bilirubin concentrations are positively associated with serum C-peptide levels in patients with Type 2 diabetes. Chung JO; Cho DH; Chung DJ; Chung MY Diabet Med; 2014 Nov; 31(11):1316-22. PubMed ID: 24910105 [TBL] [Abstract][Full Text] [Related]
9. Anti-Diabetic Activities of Gastrodia elata Blume Water Extracts Are Mediated Mainly by Potentiating Glucose-Stimulated Insulin Secretion and Increasing β-Cell Mass in Non-Obese Type 2 Diabetic Animals. Yang HJ; Kim MJ; Kwon DY; Kim DS; Lee YH; Kim JE; Park S Nutrients; 2016 Mar; 8(3):161. PubMed ID: 26978400 [TBL] [Abstract][Full Text] [Related]
11. Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better". Kaneto H; Matsuoka TA; Kimura T; Obata A; Shimoda M; Kamei S; Mune T; Kaku K J Diabetes; 2016 Mar; 8(2):183-9. PubMed ID: 26223490 [TBL] [Abstract][Full Text] [Related]
12. A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro. Al-Romaiyan A; Liu B; Asare-Anane H; Maity CR; Chatterjee SK; Koley N; Biswas T; Chatterji AK; Huang GC; Amiel SA; Persaud SJ; Jones PM Phytother Res; 2010 Sep; 24(9):1370-6. PubMed ID: 20812281 [TBL] [Abstract][Full Text] [Related]
13. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. van Poppel PC; van Asseldonk EJ; Holst JJ; Vilsbøll T; Netea MG; Tack CJ Diabetes Obes Metab; 2014 Dec; 16(12):1269-73. PubMed ID: 25039318 [TBL] [Abstract][Full Text] [Related]
14. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. Weng J; Retnakaran R; Ariachery C A; Ji L; Meneghini L; Yang W; Woo JT Diabetes Metab Res Rev; 2015 Sep; 31(6):537-44. PubMed ID: 25196375 [TBL] [Abstract][Full Text] [Related]
15. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360 [TBL] [Abstract][Full Text] [Related]
16. [Pancreatic pacemaker out of rhythm. Disturbed pulsatile insulin release therapeutically interesting in type 2 diabetes]. Sjöholm A Lakartidningen; 2007 Aug 8-21; 104(32-33):2228-9. PubMed ID: 17822199 [No Abstract] [Full Text] [Related]
17. Defining and characterizing the progression of type 2 diabetes. Fonseca VA Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S151-6. PubMed ID: 19875543 [No Abstract] [Full Text] [Related]
18. Insulin secretory function in type 2 diabetes: Does it matter how you measure it? Reaven GM J Diabetes; 2009 Sep; 1(3):142-50. PubMed ID: 20923533 [TBL] [Abstract][Full Text] [Related]
19. Protection of pancreatic beta-cells: is it feasible? Bonora E Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375 [TBL] [Abstract][Full Text] [Related]
20. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345 [No Abstract] [Full Text] [Related] [Next] [New Search]